Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HLS Therapeutics Inc.
Toronto, Ontario, Canadahlstherapeutics.com ↗
- Ownership
- Public · HLS
- Employees
- ~92
- Development stage
- Other
01
Overview
HLS Therapeutics manages a portfolio of commercial stage branded medicines including CLOZARIL (clozapine) and VASCEPA (icosapent ethyl). In Q1 2024, product sales in Canada increased 3.5% compared to Q1 2023, led by growth in Vascepa sales. The company expects 2024 consolidated revenue in the range of $60-62 million and Adjusted EBITDA of $17-19 million.[2][10]
- Therapeutic areas
- PsychiatryCardiovascular
- Modalities
- Small molecules
- Industry
- Biotech
02
Partnerships
Pfizer Inc. (being terminated in 2024)Saladax Biomedical Inc.
03
Financials
- Market cap
- $97.6M
- Total revenue
- $56.5M
- Enterprise value
- $125.7M
Beyond the preview
Go deeper on HLS Therapeutics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLS Therapeutics Inc..